Table 2 Antimicrobial susceptibility profile of the ESBL-producing Enterobacterales isolates showing the susceptible proportion
Antibiotic | Total isolates (N = 142) n (%) | E. coli (N = 108) n (%) | K.pneumoniae (N = 23) n (%) | Citrobacter spp (N = 5) n (%) | Acinetobacter spp (N = 4) n (%) | Enterobacter spp (N = 2) n (%) |
|---|---|---|---|---|---|---|
Meropenem | 138 (97.2) | 107 (99.1) | 21 (91.3) | 5 (100.0) | 3 (75.0) | 2 (100.0) |
Amoxicillin-Clavulanate | 34 (23.9) | 32 (29.6) | 2 (8.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Ceftriaxone | 9 (6.3) | 1 (0.9) | 4 (17.4) | 1 (20.0) | 2 (50.0) | 1 (50.0) |
Piperacillin-tazobactam | 77 (54.2) | 48 (44.4) | 20 (87) | 4 (80.0) | 3 (75.0) | 2 (100.0) |
Cefepime | 30 (21.1) | 19 (17.6) | 5 (21.7) | 4 (80.0) | 2 (50.0) | 0 (0.0) |
Ciprofloxacin | 43 (30.2) | 24 (22.2) | 14 (60.9) | 3 (60.0) | 1 (25.0) | 1 (50.0) |
Gentamycin | 85 (59.9) | 60 (55.5) | 15 (65.2) | 5 (100.0) | 4 (100.0) | 1 (50.0) |
Cefoxitin | 74 (52.1) | 57 (52.8) | 14 (60.9) | 0 (0.0) | 1 (25.0) | 2 (100.0) |
Ceftazidime | 6(4.2) | 2 (1.8) | 2 (8.7) | 0 (0.0) | 2 (50.0) | 0 (0.0) |
Cefotaxime | 3 (2.1) | 0 (0.0) | 3 (13.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Aztreonam | 21 (14.8) | 5 (4.6) | 8 (34.8) | 2 (40.0) | 4 (10.0) | 2 (100.0) |
Temocillin | 100 (70.4) | 79 (73.1) | 20 (87) | 1 (20.0) | 0 (0.0) | 0 (0.0) |
Chloramphenicol | 85 (59.9) | 61 (56.5) | 18 (78.2) | 5 (100.0) | 0 (0.0) | 1 (50.0) |
Tetracycline | 18 (12.7) | 7 (6.5) | 6 (26.1) | 3 (60.0) | 2 (50.0) | 0 (0.0) |
Sulfamethoxazole | 24 (16.9) | 4 (3.7) | 12 (52.2) | 4 (80.0) | 4 (100.0) | 0 (0.0) |